Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-02-24 14:50 CET (UTC+1h)
 

Sample size for 4-period 4-sequence crossover BE study [Power / Sample Size]

posted by Bryony Simmons - UK, 2018-02-01 12:16  - Posting: # 18320
Views: 2,051

Hi,

I am in the process of conducting a sample size calculation for a crossover BE study. There are four-treatments (2xreference dosages & 2xtreatment dosages) & I plan to use the Williams' design as follows:

ABCD
BDAC
CADB
DCBA

The coefficient of variation from previous studies is 20% & I am assuming the true test reference ratio to be between 0.95 and 1.05. I want to demonstrate bioequivalence (0.80-1.25) at 90% power at the 5% level.

Using these figures, if it was a standard AB/BA crossover, I estimate that I would require 12 individuals to complete each arm - is this correct? I am unsure how this calculation is extended to fit the 4x4 design - do I simply randomise 12 more individuals to each of the remaining two sequences?

Further, if I planned to have just 1 treatment dose changing the design as follows:

ABC
BCA
CAB

Is it reasonable to randomise 12 individuals per sequence?

I really appreciate any help on this question.

Best wishes,
Bryony


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,940 Posts in 3,822 Threads, 1,122 registered users;
29 users online (0 registered, 29 guests).

In general, scientific progress calls for no more
than the absorption and elaboration of new ideas –
and this is a call most scientists are happy to heed.    Werner Heisenberg

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed